序贯来曲唑/促性腺激素用于多囊卵巢综合征不孕女性诱导排卵:一项随机对照试验
该开放标签随机对照试验纳入174例多囊卵巢综合征不孕女性,按1:1随机分为来曲唑组(87例)和序贯来曲唑/HMG组(87例),比较一个治疗周期的排卵与妊娠结局。序贯组排卵率(90.8% vs 70.1%,P=0.001)和活产率(23.0% vs 10.3%,P=0.025)均显著高于来曲唑组,不良事件无统计学差异。数据提示序贯方案在诱导排卵和促进妊娠方面可能优于单用来曲唑。
要点
- 序贯来曲唑/HMG组排卵率90.8%,显著高于来曲唑组的70.1%(P=0.001)。
- 序贯组活产率23.0%,显著高于来曲唑组的10.3%(P=0.025)。
- 两组不良事件无统计学差异,数据提示序贯方案可能优于单用来曲唑。
核心结论
- 数据提示,序贯来曲唑/HMG方案在PCOS不孕女性的诱导排卵和促进妊娠方面可能优于单用来曲唑方案。
研究设计与样本
- 开放标签随机对照试验,2019年8月至2020年1月在华中科技大学同济医学院附属协和医院纳入174例受试者。
- 纳入18至40岁、符合Rotterdam标准且无其他已知不孕原因的PCOS不孕女性。
- 按1:1随机分为来曲唑组(n=87)和序贯来曲唑/HMG组(n=87),各治疗一个周期。
- 来曲唑组于周期第3-7天给予来曲唑2.5 mg;序贯组于周期第3-7天给予来曲唑2.5 mg,并于周期第8-10天序贯注射HMG 75 IU。
- 一个治疗周期后记录妊娠结局。
主要发现
- 序贯组排卵率90.8%,来曲唑组70.1%,序贯组显著更高(P=0.001)。
- 序贯组活产率23.0%,来曲唑组10.3%,序贯组显著更高(P=0.025)。
- 两组不良事件无统计学差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Is sequential letrozole/human menopausal gonadotrophin (HMG) superior to letrozole alone in ovulation induction and pregnancy promotion among infertile women with polycystic ovary syndrome (PCOS)? DESIGN: This open-label randomized controlled trial comparing sequential letrozole/HMG and letrozole alone included 174 participants enrolled from August 2019 to January 2020 at the Union Hospital of Tongji Medical College, Huazhong University of Science and Technology. Infertile women aged between 18 and 40 years who met Rotterdam criteria for PCOS and without other known causes of infertility were selected for this study. Patients were randomly assigned at a 1:1 ratio to receive 2.5 mg letrozole on cycle days 3-7 (n = 87) or 2.5 mg letrozole on cycle days 3-7 with a sequential injection of 75 IU HMG on cycle days 8-10 for one treatment cycle (n = 87). The pregnancy outcome was recorded after one treatment cycle. RESULTS: Women receiving sequential treatment achieved a significantly higher ovulation rate than those in the letrozole group (90.8% versus 70.1%, P = 0.001) and the live birth rate of the sequential group was significantly higher than that of the letrozole protocol (23.0% versus 10.3%, P = 0.025); there was no statistical variation with respect to adverse events. CONCLUSIONS: The data suggest that the sequential letrozole/HMG protocol may be superior to the letrozole alone protocol in terms of ovulation induction and pregnancy promotion among infertile women with PCOS.
引用
- Dai X, Li J, Fu T, et al. Ovulation induction using sequential letrozole/gonadotrophin in infertile women with PCOS: a randomized controlled trial. Reprod Biomed Online. 2022. PMID: 36566146. doi:10.1016/j.rbmo.2022.08.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。